← ANALYST RATINGS · TIPRANKS
Keros Therapeutics (KROS): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $20.00, the highest $23.00, the lowest $17.00. The average is +87.6% from the last price of $10.66.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $12.00−4.0% | Hold | +12.6% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 | Hold | +12.6% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +7.9% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.50 → $12.00−4.0% | Hold | +12.6% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $12.00−4.0% | Hold | +12.6% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.50−4.2% | Hold | +7.9% | Reiterated | 29.09.26on TipRanks 17:05 | — | |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $18.00 | Buy | +68.9% | Reiterated | 02.09.26on TipRanks 11:05 | +1.0%next day −2.1% · 5 days +0.4% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $20.00 → $17.00−15.0% | Hold | +59.5% | Reiterated | 11.08.26on TipRanks 09:00 | −0.1%next day +5.0% · 5 days +0.1% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $16.00 | Hold | +50.1% | Reiterated | 04.08.26on TipRanks 15:55 | −0.4%next day −2.3% · 5 days +3.9% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $20.00 | Buy | +87.6% | Reiterated | 04.08.26on TipRanks 06:12 | −0.4%next day −2.3% · 5 days +3.9% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $30.00 → $23.00−23.3% | Buy | +115.8% | Reiterated | 04.08.26on TipRanks 06:06 | −0.4%next day −2.3% · 5 days +3.9% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Hold | — | Reiterated | 04.08.26on TipRanks 04:22 | −0.4%next day −2.3% · 5 days +3.9% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 15.05.26on TipRanks 08:25 | −3.3%next day −3.2% · 5 days +5.7% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $23.00 → $20.00−13.0% | Buy | +87.6% | Reiterated | 05.03.26on TipRanks 20:35 | −2.2%next day −0.4% · 5 days −1.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Hold | — | Reiterated | 05.11.25on TipRanks 20:10 | +4.4%next day +0.1% · 5 days +6.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Keros Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $18.80 at a price of $11.40 (+64.9%); now: $18.80 at $10.66 (+76.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 1 | 2 | 2 | 2 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.94 (from $-1.71 to $-0.47). Last quarter: $-1.45.
Sales
Next quarter’s sales estimate — $15M (from $0M to $20M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Keros Therapeutics
- CEO: Jasbir S. Seehra
- Employees: 92
- 1050 Waltham Street, Lexington, MA, 02421, US
- www.kerostx.com
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Data from the stock’s TipRanks forecast page, read 51 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗